Abstract: This invention provides isolated nucleic acid molecules encoding a mammalian glycine transporter, isolated nucleic acid molecules encoding a human glycine transporter, isolated proteins which are mammalian glycine transporter proteins, isolated proteins which are human glycine transporter proteins, vectors comprising isolated nucleic acid molecules encoding a mammalian or a human glycine transporter, mammalian cells comprising such vectors, antibodies directed to a mammamlian glycine transporter, antibodies directed to a human glycine transporter, nucleic acid probes useful for detecting nucleic acid encoding mammalian glycine transporter, nucleic acid probes useful for detecting nucleic acid encoding human glycine transporter, antisense oligonucleotides complementary to any sequences of a nucleic acid molecule which encodes a mammalian glycine transporter, antisense oligonucleotides complementary to any sequences of a nucleic said molecule which encodes a human glycine transporter, pharmaceutical compounds r

Abstract: This invention is directed to tricyclic compounds which are selective antagonists for NPY (Y5) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier.

Abstract: This invention provides a recombinant nucleic acid comprising a nucleic acid encoding a mammalian SNORF1 receptor, wherein the mammalian receptor-encoding nucleic acid hybridizes under high stringency conditions to (a) a nucleic acid encoding a human SNORF1 receptor and having a sequence identical to the sequence of the human SNORF1 receptor-encoding nucleic acid contained in plasmid pEXJ-hSNORF1-f (ATCC Accession No. 203898) or (b) a nucleic acid encoding a rat SNORF1 receptor and having a sequence identical to the sequence of the rat SNORF1 receptor-encoding nucleic acid contained in plasmid pcDNA3.1-rSNORF1-f (ATCC Accession No. 203897). This invention further provides a recombinant nucleic acid comprising a nucleic acid encoding a human SNORF1 receptor, wherein the human SNORF1 receptor comprises an amino acid sequence identical to the sequence of the human SNORF1 receptor encoded by the shortest open reading frame indicated in FIGS. 1A-1B (Seq. I.D. No. 1).

Abstract: This invention provides an isolated nucleic acid molecule encoding a human 5-HT.sub.1E receptor, an isolated protein which is a human 5-HT.sub.1E receptor, vectors comprising an isolated nucleic acid molecule encoding a human 5-HT.sub.1E receptors, mammalian cells comprising such vectors, antibodies directed to the human 5-HT.sub.1E receptor, nucleic acid probes useful for detecting nucleic acid encoding human 5-HT.sub.1E receptors, antisense oligonucleotides complementary to any sequences of a nucleic acid molecule which encodes a human 5-HT.sub.1E at receptor, pharmaceutical compounds related to human 5-HT.sub.1E receptors, and nonhuman transgenic animals which express DNA a normal or a mutant human 5-HT.sub.1E receptor. This invention further provides methods for determining ligand binding, detecting expression, drug screening, and treatment involving the human 5-HT.sub.1E receptor.

Abstract: This invention is directed to novel imidazole and imidazoline derivatives which are selective agonists for cloned human a, adrenergic receptors. This invention is also related to the use of these compounds for the treatment of any disease where modulation of the .alpha..sub.2 receptors may be useful. The invention further provides for a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier.

Abstract: This invention provides an isolated nucleic acid molecule encoding a mammalian 5-HT.sub.4B receptor and an isolated nucleic acid molecule encoding a human 5-HT.sub.4B receptor, an isolated protein which is a mammalian 5-HT.sub.4B receptor, an isolated protein which is a human 5-HT.sub.4B receptor, vectors comprising an isolated nucleic acid molecule encoding a mammalian 5-HT.sub.4B receptor, vectors comprising an isolated nucleic acid molecule encoding a human 5-HT.sub.4B receptor, mammalian cells comprising such vectors, antibodies directed to the 5-HT.sub.4B receptor, nucleic acid probes useful for detecting nucleic acid encoding a mammalian or human 5-HT.sub.4B receptor, antisense oligonucleotides complementary to any sequences of a nucleic acid molecule which encodes a mammalian or human 5-HT.sub.4B receptor, pharmaceutical compounds related to the human 5-HT.sub.4B receptor, and nonhuman transgenic animals which express DNA encoding a normal or a mutant mammalian or human 5-HT.sub.4B receptor.

Abstract: This invention provides an isolated nucleic acid, vectors, transformed mammalian cells and non-human transgenic animals that encode and express normal or mutant .alpha. 1a, .alpha. 1b and .alpha. 1c adrenergic receptor genes. This invention also provides a protein, and an antibody directed to the protein and pharmaceutical compounds related to .alpha. 1a, .alpha. 1b and .alpha. 1c adrenergic receptors. This invention provides nucleic acid probes, and antisense oligonucleotides complementary to .alpha. 1a, .alpha. 1b and .alpha. 1c adrenergic receptor genes. This invention further provides methods for determining ligand binding, detecting expression, drug screening, and treatments for alleviating abnormalities associated with human .alpha. 1a, .alpha. 1b and .alpha. 1c adrenergic receptors.

Abstract: This invention is directed to imidazolones which are selective antagonists for human .alpha..sub.1a receptors. This invention is also related to uses of these compounds for lowering intraocular pressure, inhibiting cholesterol synthesis, relaxing lower urinary tract tissue, the treatment of benign prostatic hyperplasia, impotency, cardiac arrhythmia, sympathetic mediated pain, migraine, and for the treatment of any disease where the antagonism of the .alpha..sub.1a receptor may be useful. The invention further provides a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier.

Abstract: This invention is directed to novel indole and benzothiazole compounds which are selective for cloned human alpha 2 receptors. This invention is also related to uses of these compounds for any indication where use of an alpha 2 agonist may be appropriate. Specifically, this includes use as analgesic, sedative and anaesthetic agents. In addition, this invention includes using such compounds for lowering intraocular pressure, presbyopia, treating migraine, hypertension, alcohol withdrawal, drug addiction, rheumatoid arthritis, ischemic pain, spasticity, diarrhea, nasal decongestion, urinary incontinence as well as for use as cognition enhancers and ocular vasoconstriction agents. The invention further provides a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier.

Abstract: A method of treating benign prostatic hyperplasia in a subject which comprises administering to the subject a therapeutically effective amount of a compound which binds to a human .alpha..sub.1C adrenergic receptor with a binding affinity greater than ten-fold higher than the binding affinity with which the compound binds to a human .alpha..sub.1A adrenergic receptor, a human .alpha..sub.1B adrenergic receptor, and a human histamine H.sub.1 receptor, and, binds to a human .alpha..sub.2 adrenergic receptor with a binding affinity which is greater than ten-fold lower than the binding affinity with which the compound binds to such .alpha..sub.1C adrenergic receptor. Compounds meeting these criteria are provided.

Abstract: This invention provides a method of treating benign prostatic hyperplasia in a subject which comprises administering to the subject a therapeutically effective amount of an .alpha..sub.1C antagonist which (a) binds to a human .alpha..sub.1C adrenergic receptor with a binding affinity greater than 100-fold higher than the binding affinity with which the .alpha..sub.1C antagonist binds to a human .alpha..sub.1A adrenergic receptor, a human .alpha..sub.1B adrenergic receptor, and a human histamine H.sub.1 receptor; and (b) binds to a human .alpha..sub.2 adrenergic receptor with a binding affinity which is greater than 100-fold lower than the binding affinity with which the .alpha..sub.1C antagonist binds to such .alpha..sub.1C adrenergic receptor.The invention further provides a method of inhibiting contraction of a prostate tissue which comprises contacting the prostate tissue with an effective contraction-inhibiting amount of an .alpha..sub.1C antagonist which (a) binds to a human .alpha..sub.

Abstract: This invention provides isolated nucleic acid molecules encoding a human and a rat Y2 receptor, an isolated protein which is a human or rat Y2 receptor, vectors comprising an isolated nucleic acid molecule encoding a human or rat Y2 receptors, mammalian cells comprising such vectors, antibodies directed to the human or rat Y2 receptor, nucleic acid probes useful for detecting nucleic acid encoding human or rat Y2 receptors, antisense oligonucleotides complementary to any sequences of a nucleic acid molecule which encodes a human or rat Y2 receptor, pharmaceutical compounds related to human or rat Y2 receptors, and nonhuman transgenic animals which express DNA a normal or a mutant human or rat Y2 receptor. This invention further provides methods for determining ligand binding, detecting expression, drug screening, and treatment involving the human or rat Y2 receptor.

Abstract: This invention provides methods of modifying feeding behavior, including increasing or decreasing food consumption, e.g., in connection with treating obesity, bulimia or anorexia. These methods involve administration of compounds that are selective agonists or antagonists for the Y5 receptor. One such compound has the structure: ##STR1## In addition, this invention provides an isolated nucleic acid molecule encoding a Y5 receptor, an isolated Y5 receptor protein, vectors comprising an isolated nucleic acid molecule encoding a Y5 receptor, cells comprising such vectors, antibodies directed to the Y5 receptor, nucleic acid probes useful for detecting nucleic acid encoding Y5 receptors, antisense oligonucleotides complementary to any unique sequences of a nucleic acid molecule which encodes a Y5 receptor, and nonhuman transgenic animals which express DNA encoding a normal or a mutant Y5 receptor.

Abstract: This invention provides methods for determining whether a chemical compound specifically binds to and activates or inhibits activation of a human or rat Y4 receptor.

Abstract: This invention provides an isolated nucleic acid encoding a mammalian galanin receptor, an isolated galanin receptor protein, vectors comprising an isolated nucleic acid encoding a galanin receptor, cells comprising such vectors, antibodies directed to the galanin receptor, nucleic acid probes useful for detecting nucleic acid encoding galanin receptors, antisense oligonucleotides complementary to unique sequences of a nucleic acid encoding a galanin receptor, nonhuman transgenic animals which express DNA encoding a normal or a mutant galanin receptor, as well as methods of determining binding of compounds to the galanin receptor.

Abstract: This invention provides methods of modifying feeding behavior, including increasing or decreasing food consumption, e.g., in connection with treating obesity, bulimia or anorexia. These methods involve administration of compounds are selective agonists or antagonists or the Y5 receptor. One such compound has the structure: ##STR1## In addition, this invention provides an isolated nucleic acid molecule encoding a Y5 receptor, an isolated Y5 receptor protein, vectors comprising an isolated nucleic acid molecule encoding a Y5 receptor, cells comprising such vectors, antibodies directed to the Y5 receptor, nucleic acid probes useful for detecting nucleic acid encoding Y5 receptors, antisense oligonucleotides complementary to any unique sequences of a nucleic acid molecule which encodes a Y5 receptor, and nonhuman transgenic animals which express DNA a normal or a mutant Y5 receptor.

Abstract: This invention provides an isolated nucleic acid molecule encoding a human Y4 receptor, an isolated protein which is a human Y4 receptor, vectors comprising an isolated nucleic acid molecule encoding a human Y4 receptors, mammalian cells comprising such vectors, antibodies directed to the human Y4 receptor, nucleic acid probes useful for detecting nucleic acid encoding human Y4 receptors, antisense oligonucleotides complementary to any sequences of a nucleic acid molecule which encodes a human Y4 receptor, pharmaceutical compounds related to human Y4 receptors, and nonhuman transgenic animals which express DNA a normal or a mutant human Y4 receptor. This invention further provides methods for determining ligand binding, detecting expression, drug screening, and treatment involving the human Y4 receptor.

Abstract: This invention is directed to indole and benzothiazole compounds which are selective for cloned human alpha 2 receptors. This invention is also related to uses of these compounds for any indication where use of an alpha 2 agonist may be appropriate. Specifically, this includes use as analgesic, sedative and anaesthetic agents. In addition, this invention includes using such compounds for lowering intraocular pressure, presbyopia, treating migraine, hypertension, alcohol withdrawal, drug addiction, rheumatoid arthritis, ischemic pain, spasticity, diarrhea, nasal decongestion, urinary incontinence as well as for use as cognition enhancers and ocular vasoconstriction agents. The invention further provides a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier.

Abstract: This invention is directed to dihydropyrimidine compounds which are selective antagonists for human .alpha..sub.1C receptors and which have the structure: ##STR1## wherein A is aryl; R.sub.1, R.sub.2 and R.sub.3 are alkyl or heteroalkyl; R.sub.4 is heterocyclic alkyl; and X is S, O or NR.sub.3. This invention also relates to use of these compounds for the treatment of benign prostatic hyperplasia and other diseases where antagonism of the human .alpha..sub.1C receptor is useful. The invention further provides pharmaceutical compositions comprising a therapeutically effective amount of such a compound and a pharmaceutically acceptable carrier.

Abstract: This invention provides isolated nucleic acid molecules encoding human 5-HT.sub.1D receptors, isolated proteins which are human 5-HT.sub.1D receptors, vectors comprising isolated nucleic acid molecules encoding human 5-HT.sub.1D receptors, mammalian cells comprising such vectors, antibodies directed to human 5-HT.sub.1D receptors, nucleic acid probes useful for detecting nucleic acid encoding human 5-HT.sub.1D receptors, antisense oligonucleotides complementary to any sequences of a nucleic acid molecule which encodes a human 5-HT.sub.1D receptor, pharmaceutical compounds related to human 5-HT.sub.1D receptors, and nonhuman transgenic animals which express DNA which encodes a normal or a mutant human 5-HT.sub.1D receptor. This invention further provides methods for determining ligand binding, detecting expression, drug screening, and treatment involving the human 5-HT.sub.1D receptor.